Just to add a little bit to this thread. I believe Dan Welch (ITMN) was the CEO of Triangle at the time of the sale to Gilead. Also I believe he worked for Warburg as a consultant for some time after that.
As far as falling in love with biotech and feeling cheated. I will admit to both on TKT. In defense the CEO at the time of the deal Michael Astrue also felt that way. So much so in fact that he actually resigned. There were a couple of Warburg board members who pushed for the deal (I don't like having them on ITMN's board should Pirfenidone succeed anyway). The premise was they had Hunter data (MPS II) just around the corner and Shire would have likely backed out if the data were bad. He (Astrue) strongly felt the data would be positive and the company worth substantially more upon results (which turned out to be positive). They (Shire/TKT mouth pieces) claimed the pricing reflected success.
Market Data 
Markets 
AI
